Frellick M. AMA declares obesity a disease. Medscape Medical News. 2013. Available at: https://www.medscape.com/viewarticle/806566.https://www.medscape.com/viewarticle/806566
Frellick M. AMA declares obesity a disease. Medscape Medical News. 2013. Available at: https://www.medscape.com/viewarticle/806566.https://www.medscape.com/viewarticle/806566
Aguilera C., Labbé T., Busquets J., Venegas P., Neira C., Valenzuela A. Obesity: risk factor or primary disease? Rev Med Chil. 2019;147(4):470–474. doi: 10.4067/S0034-98872019000400470..
DOI: 10.4067/S0034-98872019000400470
Ng M., Fleming T., Robinson M., Thomson B., Graetz N., Margono C. et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet. 2014;384(9945):766–781. doi: 10.1016/S0140-6736(14)60460-8..
DOI: 10.1016/S0140-6736(14)60460-8
Spoer B., Fullilove R. Obesity: a syndemics perspective. Clin Obes. 2016;6(3):171–174. doi: 10.1111/cob.12141..
DOI: 10.1111/cob.12141
Yeh T.L., Chen H.H., Chiu H.H., Chiu Y.H., Hwang L.C., Wu S.L. Morbidity associated with overweight and obesity in health personnel: a 10-year retrospective of hospital-based cohort study in Taiwan. Diabetes Metab Syndr Obes. 2019;12:267–274. doi: 10.2147/DMSO.S193434..
DOI: 10.2147/DMSO.S193434
Schwartz M.W., Seeley R.J., Zeltser L.M., Drewnowski A., Ravussin E., Redman L.M. et al. Obesity Pathogenesis: An Endocrine Society Scientific Statement. Endocr Rev. 2017;38(4):267–296. doi: 10.1210/er.2017-00111..
DOI: 10.1210/er.2017-00111
Misra A., Jayawardena R., Anoop S. Obesity in South Asia: Phenotype, Morbidities, and Mitigation. Curr Obes Rep. 2019;8(1):43–52. doi: 10.1007/s13679-019-0328-0..
DOI: 10.1007/s13679-019-0328-0
McIntyre A. Burden of illness review of obesity: are the true costs realised? RSPH. 1998;118(2):76–84. doi: 10.1177/146642409811800207..
DOI: 10.1177/146642409811800207
Bray G., Kim K.K., Wilding J.P.H. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715–723. doi: 10.1111/obr.12551..
DOI: 10.1111/obr.12551
Diabetes Prevention Program Research Group; Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403. doi: 10.1056/NEJMoa012512..
DOI: 10.1056/NEJMoa012512
Diabetes Prevention Program Research Group; Nathan D.M., Barrett-Connor E., Crandall J.P., Edelstein S. L., Goldberg R.B., Horton E.S. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet. Diabetes Endocrinol. 2015;3(11):866–875. doi: 10.1016/S2213-8587(15)00291-0..
DOI: 10.1016/S2213-8587(15)00291-0
Yazıcı D., Sezer H. Insulin Resistance, Obesity and Lipotoxicity. In: Engin A., Engin A. (eds.) Obesity and Lipotoxicity. Advanced Experimental Medicine and Biology; 2017. doi: 10.1007/978-3-319-48382-5_12..
DOI: 10.1007/978-3-319-48382-5_12
Bodhini D., Mohan V. Mediators of insulin resistance & cardiometabolic risk: Newer insights. Indian J Med Res. 2018;148(2):127–129. doi: 10.4103/ijmr.IJMR_969_18..
DOI: 10.4103/ijmr.IJMR_969_18
Руяткина Л.А., Руяткин Д.С., Исхакова И.С. Возможности и варианты суррогатной оценки инсулинорезистентности. Ожирение и метаболизм. 2019;16(1):27–33. doi: 10.14341/omet10082..
DOI: 10.14341/omet10082
Баланова Ю.А., Шальнова С.А., Деев А.Д., Имаева А.Э., Концевая А.В., Муромцева Г.А. и др. Ожирение в российской популяции – распространенность и ассоциации с факторами риска хронических неинфекционных заболеваний Российский кардиологический журнал. 2018;(6):123–130. doi: 10.15829/1560-4071-2018-6-123-130..
DOI: 10.15829/1560-4071-2018-6-123-130
Романцова Т.И., Сыч Ю.П. Иммунометаболизм и метавоспаление при ожирении. Ожирение и метаболизм. 2019;16(4):3–17. doi: 10.14341/omet12218..
DOI: 10.14341/omet12218
Garvey W.T., Garber A.J., Mechanick J.I., Einhorn D., Dagogo-Jack S., Einhorn D. et al.; AACE Obesity Scientific Committee. American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract. 2014;20(9):977–989. doi: 10.4158/EP14280.PS..
DOI: 10.4158/EP14280.PS
Ochner C.N., Tsai A.G., Kushner R.F., Wadden T.A. Treating obesity seriously: when recommendations for lifestyle change confront biological adaptations. Lancet. Diabetes Endocrinol. 2015;3(4):232–234. doi: 10.1016/S2213-8587(15)00009-1..
DOI: 10.1016/S2213-8587(15)00009-1
Sinclair P., Docherty N., le Roux C.W. Metabolic Effects of Bariatric Surgery. Clin Chem. 2018;64(1):72–81. doi: 10.1373/clinchem.2017.272336..
DOI: 10.1373/clinchem.2017.272336
Nainggolan L. Obesity as a “Brain Disease„; a Driver for New Therapies. 22nd European Congress on Obesity. 2015. Available at: https://www.medscape.com/viewarticle/844410.https://www.medscape.com/viewarticle/844410
Nainggolan L. Obesity as a “Brain Disease„; a Driver for New Therapies. 22nd European Congress on Obesity. 2015. Available at: https://www.medscape.com/viewarticle/844410.https://www.medscape.com/viewarticle/844410
Foretz M., Viollet B. Therapy: Metformin takes a new route to clinical efficacy. Nat Rev Endocrinol. 2015;11(7):390–392. doi: 10.1038/nrendo.2015.85..
DOI: 10.1038/nrendo.2015.85
Luo C., Wang X., Huang H., Mao X., Zhou H., Liu Z. Effect of Metformin on Antipsychotic-Induced Metabolic Dysfunction: The Potential Role of Gut- Brain Axis. Front Pharmacol. 2019;10:371. doi: 10.3389/fphar.2019.00371..
DOI: 10.3389/fphar.2019.00371
Bauer P.V., Hamr S.C., Duca F.A. Regulation of energy balance by a gutbrain axis and involvement of the gut microbiota. Cell Mol Life Sci. 2016;73(4):737–755. doi: 10.1007/s00018-015-2083-z..
DOI: 10.1007/s00018-015-2083-z
Petra A.I., Panagiotidou S., Hatziagelaki E., Stewart J. M., Conti P., Theoharides T.C. Gut-microbiota-brain axis and its effect on neuropsychiatric disorders with suspected immune dysregulation. Clin Ther. 2015;37(5):984–995. doi: 10.1016/j.clinthera.2015.04.002..
DOI: 10.1016/j.clinthera.2015.04.002
Волкова Н.И., Ганенко Л.А., Головин С.Н. Роль микробиоты кишечника в развитии ожирения и его метаболического профиля (часть II). Медицинский вестник Северного Кавказа. 2019;14(2):391–396. doi: 10.14300/mnnc.2019.14098..
DOI: 10.14300/mnnc.2019.14098
Hills R.D. Jr., Pontefract B.A., Mishcon H.R., Black C.A., Sutton S.C., Theberge C.R. Gut Microbiome: Profound Implications for Diet and Disease. Nutrients. 2019;11(7):1613. doi: 10.3390/nu11071613..
DOI: 10.3390/nu11071613
Allin K.H., Tremaroli V., Caesar R., Jensen B.A.H., Damgaard M.T.F., Bahl M.I. et al. Aberrant intestinal microbiota in individuals with prediabetes. Diabetologia. 2018;61(4):810–820. doi: 10.1007/s00125-018-4550-1..
DOI: 10.1007/s00125-018-4550-1
Paternoster S., Falasca M. Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1. Front Endocrinol. 2018;9:584. doi: 10.3389/fendo.2018.00584..
DOI: 10.3389/fendo.2018.00584
Fava G.E., Dong E.W., Wu H. Intra-islet glucagon-like peptide 1. J Diabetes Complications. 2016;30(8):1651–1658. doi: 10.1016/j.jdiacomp.2016.05.016..
DOI: 10.1016/j.jdiacomp.2016.05.016
Liu C., Wang C., Guan S., Liu H., Wu X., Zhang Z. et al. The Prevalence of Metabolically Healthy and Unhealthy Obesity according to Different Criteria. Obes Facts. 2019;12(1):78–90. doi: 10.1159/000495852..
DOI: 10.1159/000495852
Smith G.I., Mittendorfer B., Klein S. Metabolically healthy obesity: facts and fantasies. J Clin Invest. 2019;129(10):3978–3989. doi: 10.1172/JCI129186..
DOI: 10.1172/JCI129186
Longo M., Zatterale F., Naderi J., Parrillo L., Formisano P., Raciti G.A. et al. Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications. Int J Mol Sci. 2019;20(9):2358. doi: 10.3390/ijms20092358..
DOI: 10.3390/ijms20092358
Brøns C., Grunnet L.G. Mechanisms in endocrinology: Skeletal muscle lipotoxicity in insulin resistance and type 2 diabetes: a causal mechanism or an innocent bystander? Eur J Endocrinol. 2017;176(2):R67–R78. doi: 10.1530/EJE-16-0488..
DOI: 10.1530/EJE-16-0488
Hwang I., Kim J.B. Two Faces of White Adipose Tissue with Heterogeneous Adipogenic Progenitors. Diabetes Metab J. 2019;43(6):752–762. doi: 10.4093/dmj.2019.0174..
DOI: 10.4093/dmj.2019.0174
Cetinkalp S., Simsir I.Y., Ertek S. Insulin resistance in brain and possible therapeutic approaches. Curr Vasc Pharmacol. 2014;12(4):553–564. doi: 10.2174/1570161112999140206130426..
DOI: 10.2174/1570161112999140206130426
Wang B., Cheng K.K. Hypothalamic AMPK as a Mediator of Hormonal Regulation of Energy Balance. Int J Mol Sci. 2018;19(11):3552. doi: 10.3390/ijms19113552..
DOI: 10.3390/ijms19113552
Zhou Z., Tang Y., Jin X., Chen C., Lu Y., Liu L., Shen C. Metformin Inhibits Advanced Glycation End Products-Induced Inflammatory Response in Murine Macrophages Partly through AMPK Activation and RAGE/NFkappaB Pathway Suppression. J Diabetes Res. 2016;2016:4847812. doi: 10.1155/2016/4847812..
DOI: 10.1155/2016/4847812
Youn J.Y., Siu K.L., Lob H.E., Itani H., Harrison D.G., Cai H. Role of vascular oxidative stress in obesity and metabolic syndrome. Diabetes. 2014;63(7):2344–2355. doi: 10.2337/db13-0719..
DOI: 10.2337/db13-0719
Филатова Г.А., Дэпюи Т.И., Гришина Т.И. Ожирение: спорные вопросы, определяющие метаболическое здоровье. Эндокринология: Новости. Мнения. Обучение. 2018;7(1):58–67. Режим доступа: https://cyberleninka.ru/article/n/ozhirenie-spornye-voprosy-opredelyayuschie-metabolicheskoe-zdorovie.https://cyberleninka.ru/article/n/ozhirenie-spornye-voprosy-opredelyayuschie-metabolicheskoe-zdorovie
Филатова Г.А., Дэпюи Т.И., Гришина Т.И. Ожирение: спорные вопросы, определяющие метаболическое здоровье. Эндокринология: Новости. Мнения. Обучение. 2018;7(1):58–67. Режим доступа: https://cyberleninka.ru/article/n/ozhirenie-spornye-voprosy-opredelyayuschie-metabolicheskoe-zdorovie.https://cyberleninka.ru/article/n/ozhirenie-spornye-voprosy-opredelyayuschie-metabolicheskoe-zdorovie
Ye J., Kraegen T. Insulin resistance: central and peripheral mechanisms. The 2007 Stock Conference Report. Obes Rev. 2008;9(1):30–34. doi: 10.1111/j.1467-789X.2007.00402.x..
DOI: 10.1111/j.1467-789X.2007.00402.x
Gummesson A., Nyman E., Knutsson M., Karpefors M. Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(9):1295–1305. doi: 10.1111/dom.12971..
DOI: 10.1111/dom.12971
Grams J., Garvey W.T. Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action. Curr Obes Rep. 2015;4(2):287–302. doi: 10.1007/s13679-015-0155-x..
DOI: 10.1007/s13679-015-0155-x
American Diabetes Association. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S51–S54. doi: 10.2337/dc18-S005..
DOI: 10.2337/dc18-S005
Cook R.N., Appel L.J., Whelton P.K. Weight change and mortality: Long-term results from the trials of hypertension prevention. J Clin Hypertens. 2018;20(12):1666–1673. doi: 10.1111/jch.13418..
DOI: 10.1111/jch.13418
Thomas D.M., Ivanescu A.E., Martin C.K., Heymsfield S.B., Marshall K., Bodrato V.E. et al. Predicting successful long-term weight loss from short-term weight-loss outcomes: new insights from a dynamic energy balance model (the POUNDS Lost study). Am J Clin Nutr. 2015;101(3):449–454. doi: 10.3945/ajcn.114.091520..
DOI: 10.3945/ajcn.114.091520
Finer N. Predicting therapeutic weight loss. Am J Clin Nutr. 2015;101(3):419–420. doi: 10.3945/ajcn.114.106195..
DOI: 10.3945/ajcn.114.106195
Bailey C.J. Metformin: historical overview. Diabetologia. 2017;60(9):1566–1576. doi: 10.1007/s00125-017-4318-z..
DOI: 10.1007/s00125-017-4318-z
Kastuyama H., Yanai H. Does Metformin Assist New Anti-Diabetic Drugs to Succeed? J Clin Med Res. 2019;11(2):151–155. doi: 10.14740/jocmr3706..
DOI: 10.14740/jocmr3706
Yerevanian A., Soukas A.A. Metformin: Mechanisms in Human Obesity and Weight Loss. Curr Obes Rep. 2019;8(2):156–164. doi: 10.1007/s13679-019-00335-3..
DOI: 10.1007/s13679-019-00335-3
Ma W., Chen J., Meng Y., Yang J., Cui Q., Zhou Y. Metformin Alters Gut Microbiota of Healthy Mice: Implication for Its Potential Role in Gut Microbiota Homeostasis. Front Microbiol. 2018;9:1336. doi: 10.3389/fmicb.2018.01336..
DOI: 10.3389/fmicb.2018.01336
Bahne E., Hansen M., Brønden A., Sonne D.P., Vilsbøll T., Knop F.K. Involvement of Glucagon-like Peptide-1 in the Glucose-lowering effect of Metformin. Diabetes Obes Metab. 2016;18(10):955–961. doi: 10.1111/dom.12697..
DOI: 10.1111/dom.12697
Руяткина Л.А., Руяткин Д.С. Многоплановые эффекты метформина у пациентов с сахарным диабетом 2 типа. Сахарный диабет. 2017;20(3):210–219. doi: 10.14341/DM2003458-64..
DOI: 10.14341/DM2003458-64
Zilov A.V., Abdelaziz S.I., AlShammary A., Al Zahrani A., Amir A., Assaad Khalil S.H. et al. Mechanisms of action of metformin with special reference to cardiovascular protection. Diabetes Metab Res Rev. 2019;35(7):e3173. doi: 10.1002/dmrr.3173..
DOI: 10.1002/dmrr.3173
Luo F., Guo Y., Ruan G., Li X. Metformin promotes cholesterol efflux in macrophages by up-regulating FGF21 expression: a novel anti-atherosclerotic mechanism. Lipids Health Dis. 2016;15:109. doi: 10.1186/s12944-016-0281-9..
DOI: 10.1186/s12944-016-0281-9
Jing Y., Wu F., Li D., Yang L., Li Q., Li R. Metformin improves obesity-associated inflammation by altering macrophages polarization. Mol Cell Endocrinol. 2018;461:256–264. doi: 10.1016/j.mce.2017.09.025..
DOI: 10.1016/j.mce.2017.09.025
Rodriguez J., Hiel S., Delzenne N.M. Metformin: old friend, new ways of action-implication of the gut microbiome? Curr Opin Clin Nutr Metab Care. 2018;21(4):294–301. doi: 10.1097/MCO.0000000000000468..
DOI: 10.1097/MCO.0000000000000468
Ha J.-S., Yeom Y.-S., Jang J.-H., Kim Y.-H., Im J.I., Kim I.S., Yang S.-J. Antiinflammatory Effects of Metformin on Neuro-inflammation and NLRP3 Inflammasome Activation in BV-2 Microglial Cells. Biomed Sci Lett. 2019;25(1):92–98. doi: 10.15616/bsl.2019.25.1.92..
DOI: 10.15616/bsl.2019.25.1.92
Johanns M., Lai Y.C., Hsu M.F., Jacobs R., Vertommen D., Van Sande J. et al. AMPK antagonizes hepatic glucagon-stimulated cyclic AMP signalling via phosphorylation-induced activation of cyclic nucleotide phosphodiesterase 4B. Nat Commun. 2016;7:10856. doi: 10.1038/ncomms10856..
DOI: 10.1038/ncomms10856
Шпаков А.О., Деркач К.В. Молекулярные механизмы влияния метформина на функциональную активность нейронов мозга. Российский физиологический журнал им. И.М. Сеченова. 2017;103(5):504–517. Режим доступа: https://elibrary.ru/item.asp?id=29404783.https://elibrary.ru/item.asp?id=29404783
Шпаков А.О., Деркач К.В. Молекулярные механизмы влияния метформина на функциональную активность нейронов мозга. Российский физиологический журнал им. И.М. Сеченова. 2017;103(5):504–517. Режим доступа: https://elibrary.ru/item.asp?id=29404783.https://elibrary.ru/item.asp?id=29404783
Moreira P.I. Metformin in the diabetic brain: friend or foe? Ann Transl Med. 2014;2(6):54. doi: 10.3978/j.issn.2305-5839.2014.06.10..
DOI: 10.3978/j.issn.2305-5839.2014.06.10
Piskovatska V., Stefanyshyn N., Storey K.B., Vaiserman A.M., Lushchak O. Metformin as a geroprotector: experimental and clinical evidence. Biogerontology. 2019;20(1):33–48. doi: 10.1007/s10522-018-9773-5..
DOI: 10.1007/s10522-018-9773-5
Barzilai N., Crandall J.P., Kritchevsky S.B., Espeland M. A. Metformin as a Tool to Target Aging. Cell Metab. 2016;23(6):1060–1065. doi: 10.1016/j.cmet.2016.05.011..
DOI: 10.1016/j.cmet.2016.05.011
Samuel S.M., Varghese E., Kubatka P., Triggle C.R., Büsselberg D. Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer. Biomolecules. 2019;9(12):846. doi: 10.3390/biom9120846..
DOI: 10.3390/biom9120846
Safe S., Nair V., Karki K. Metformin-induced anticancer activities: recent insights. Biol Chem. 2018;399(4):321–335. doi: 10.1515/hsz-2017-0271..
DOI: 10.1515/hsz-2017-0271
Weng S., Luo Y., Zhang Z., Su X., Peng D. Effects of metformin on blood lipid profiles in nondiabetic adults: a meta-analysis of randomized controlled trials. Endocrine. 2020;67(2):305–317. doi: 10.1007/s12020-020-02190-y..
DOI: 10.1007/s12020-020-02190-y
Zhou L., Liu H., Wen X., Peng Y., Tian Y., Zhao L. Effects of metformin on blood pressure in nondiabetic patients: a meta-analysis of randomized controlled trials. J Hypertens. 2017;35(1):18–26. doi: 10.1097/HJH.0000000000001119..
DOI: 10.1097/HJH.0000000000001119
Malin S.K., Kashyap S.R. Effects of metformin on weight loss: potential mechanisms. Curr Opin Endocrinol Diabetes Obes. 2014;21(5):323–329. doi: 10.1097/MED.0000000000000095/.
DOI: 10.1097/MED.0000000000000095/
Araújo J.R., Martel F. Sibutramine effects on central mechanisms regulating energy homeostasis. Curr Neuropharmacol. 2012;10(1):49–52. doi: 10.2174/157015912799362788..
DOI: 10.2174/157015912799362788
Stritecka H., Hlubik P., Hlubik J. Targeted weight reduction using Sibutramine. Translational biomedicine. 2010;1(3:1). Available at: https://www.transbiomedicine.com/translational-biomedicine/targeted-weightreduction-using-sibutramine.pdf.https://www.transbiomedicine.com/translational-biomedicine/targeted-weightreduction-using-sibutramine.pdf
Stritecka H., Hlubik P., Hlubik J. Targeted weight reduction using Sibutramine. Translational biomedicine. 2010;1(3:1). Available at: https://www.transbiomedicine.com/translational-biomedicine/targeted-weightreduction-using-sibutramine.pdf.https://www.transbiomedicine.com/translational-biomedicine/targeted-weightreduction-using-sibutramine.pdf
Phillips C.L., Yee B.J., Trenell M.I., Magnussen J.S., Wang D., Banerjee D. et al. Changes in regional adiposity and cardio-metabolic function following a weight loss program with sibutramine in obese men with obstructive sleep apnea. J Clin Sleep Med. 2009;5(5):416–421. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2762711/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2762711/
Phillips C.L., Yee B.J., Trenell M.I., Magnussen J.S., Wang D., Banerjee D. et al. Changes in regional adiposity and cardio-metabolic function following a weight loss program with sibutramine in obese men with obstructive sleep apnea. J Clin Sleep Med. 2009;5(5):416–421. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2762711/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2762711/
Gokcel A., Gumurdulu Y., Karakose H., Melek Ertorer E., Tanaci N., Bascil Tutuncu N., Guvener N. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab. 2002;4(1):49–55. doi: 10.1046/j.1463-1326.2002.00181.x..
DOI: 10.1046/j.1463-1326.2002.00181.x
Романцова Т.И. Сибутрамин: эффективность и безопасность применения в рутинной клинической практике. Ожирение и метаболизм. 2015;12(3):18–24. doi: 10.14341/OMET2015318-24..
DOI: 10.14341/OMET2015318-24
Chen K.Y., Brychta R.J., Abdul Sater Z., Cassimatis T.M., Cero C., Fletcher L.A. et al. Opportunities and challenges in the therapeutic activation of human energy expenditure and thermogenesis to manage obesity. J Biol Chem. 2020;295(7):1926–1942. doi: 10.1074/jbc.REV119.007363..
DOI: 10.1074/jbc.REV119.007363
McGlashon J.M., Gorecki M.C., Kozlowski A.E., Thirnbeck C.K., Markan K.R., Leslie K.L. et al. Central serotonergic neurons activate and recruit thermogenic brown and beige fat and regulate glucose and lipid homeostasis. Cell Metab. 2015;21(5):692–705. doi: 10.1016/j.cmet.2015.04.008..
DOI: 10.1016/j.cmet.2015.04.008
Dedov I.I., Melnichenko G.A., Troshina E.A., Mazurina N.V., Galieva M.O. Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial. Obes Facts. 2018;11(4):335–343. doi: 10.1159/000488880..
DOI: 10.1159/000488880
Аметов А.С., Пьяных О.П., Невольникова А.О. Современные возможности управления метаболическим здоровьем у пациентов с ожирением и нарушениями углеводного обмена. Эндокринология: новости, мнения, обучение. 2020;9(1):80–88. Режим доступа: http://reduxin.ru/upload/iblock/285/sovremennie_vozmojnosti.pdf.http://reduxin.ru/upload/iblock/285/sovremennie_vozmojnosti.pdf
Аметов А.С., Пьяных О.П., Невольникова А.О. Современные возможности управления метаболическим здоровьем у пациентов с ожирением и нарушениями углеводного обмена. Эндокринология: новости, мнения, обучение. 2020;9(1):80–88. Режим доступа: http://reduxin.ru/upload/iblock/285/sovremennie_vozmojnosti.pdf.http://reduxin.ru/upload/iblock/285/sovremennie_vozmojnosti.pdf